Examples of 'moderate hepatic impairment' in a sentence
Meaning of "moderate hepatic impairment"
The phrase 'moderate hepatic impairment' is a medical term used to describe a condition where the liver (hepatic) is functioning at a moderately reduced capacity. It indicates that there is a moderate level of liver damage or dysfunction, which can have implications for the individual's overall health and may require medical intervention or treatment
How to use "moderate hepatic impairment" in a sentence
Basic
Advanced
moderate hepatic impairment
No dose adjustment is required in mild to moderate hepatic impairment.
Use in patients with moderate hepatic impairment or biliary obstruction.
Limited information is available in patients with moderate hepatic impairment.
Mild to moderate hepatic impairment.
Or regarding pharmacokinetics in moderate hepatic impairment.
Mild to moderate hepatic impairment had little effect on quinidine pharmacokinetics.
Mg once daily in subjects with moderate hepatic impairment.
Moderate hepatic impairment did not affect the pharmacokinetics of eslicarbazepine acetate.
Rasagiline use in patients with moderate hepatic impairment should be avoided.
Data are insufficient to draw conclusions regarding pharmacokinetics in moderate hepatic impairment.
Patients with mild or moderate hepatic impairment should be monitored closely.
Closely monitor patients with mild and moderate hepatic impairment.
In patients with moderate hepatic impairment the exposure of ospemifene and.
Qtern can be used in patients with mild or moderate hepatic impairment.
Mild and moderate hepatic impairment had no impact on the pharmacokinetic of teriflunomide.
See also
No dose adjustment is needed in patients with mild to moderate hepatic impairment.
Patients with moderate hepatic impairment showed an increased frequency of adverse reactions.
Data are insufficient to draw conclusions in patients with moderate hepatic impairment.
Patients with mild and moderate hepatic impairment were included in clinical trials.
There is no need for dose adjustment in mild to moderate hepatic impairment.
Patients with moderate hepatic impairment should be evaluated prior to initiation and during treatment.
No dose adjustment is required in patients with mild to moderate hepatic impairment.
In patients with mild to moderate hepatic impairment Onduarp should be administered with caution.
No dose adjustment is required in patients with mild or moderate hepatic impairment.
In patients with mild to moderate hepatic impairment the posology should not exceed Tolucombi.
Xultophy can be used in patients with mild or moderate hepatic impairment.
For adults with moderate hepatic impairment Child-Pugh score.
Closer monitoring is advised in patients with mild or moderate hepatic impairment.
In subjects with moderate hepatic impairment i . e.
There were no relevant changes in pharmacokinetics of oritavancin in subjects with moderate hepatic impairment.
The use of nelfinavir in patients with moderate hepatic impairment has not been studied.
Degarelix has been investigated in a pharmacokinetic study in patients with mild to moderate hepatic impairment.
Effects of mild and moderate hepatic impairment were evaluated in a single dose phase 1 study.
No dose adjustment is considered necessary unless moderate hepatic impairment exists.
In patients with mild to moderate hepatic impairment telmisartan / amlodipine should be administered with caution.
Dose adjustment is not necessary in patients with mild or moderate hepatic impairment.
Individuals with moderate hepatic impairment should start at 5 mg of Levitra.
Odefsey should be used with caution in patients with moderate hepatic impairment.
Mg for moderate hepatic impairment from one 50 mg vial.
No dose adjustment is necessary for patients with mild to moderate hepatic impairment.
Hepatic impairment For patients with moderate hepatic impairment dose reduction should be considered ( see section 4.4 ).
No dose adjustment is needed for patients with mild to moderate hepatic impairment.
Subjects with moderate hepatic impairment ( Child-Pugh B ) showed higher plasma concentrations of lacosamide approximately 50 % higher AUCnorm.
No dose adjustment is deemed necessary in patients with mild or moderate hepatic impairment.
For patients with moderate hepatic impairment ( Child-Pugh Class B ), a dose reduction is recommended.
No dose adjustment is recommended for patients with mild or moderate hepatic impairment.
Patients with moderate hepatic impairment ( Child Pugh B ) showed a higher exposure to this medicine see section 5.2.
Zontivity should be used with caution in patients with moderate hepatic impairment.
Mg for moderate hepatic impairment ( from one 50 mg vial ) at reduced volume.
No dose adjustment of cobicistat is required in patients with mild or moderate hepatic impairment.
You'll also be interested in:
Examples of using Hepatic
Show more
Progressive renal or hepatic end organ dysfunction
Hepatic toxicity has been associated with acetaminophen
Monitoring of the hepatic function is also recommended
Examples of using Moderate
Show more
There are moderate to large amounts of ketones in urine
Most undesirable effects were mild to moderate in severity
Exert only moderate pressure on the workpi
Examples of using Impairment
Show more
An impairment test is realized during each closing
You have a neurological impairment called somatoparaphrenia
Impairment testing is done at the individual investment level
